Characteristics | Platelet-to-lymphocyte ratio | P value | ||
---|---|---|---|---|
<90 | 90–311 | ≥312 | ||
Platelet-to-lymphocyte ratio | 59.1 | 182.6 | 456.8 | <0.001 |
Clinical parameters, n (%) | 1708 | 6699 | 2454 | Â |
Age, years | 62.3 (15.9) | 65.4 (15.9) | 65.7 (15.5) | <0.001 |
Sex, n (%) | Â | Â | Â | <0.001 |
 Male | 992 (58.1) | 3679 (54.9) | 1260 (51.3) |  |
 Female | 716 (41.9) | 3018 (45.1) | 1194 (48.7) |  |
Ethnicity, n (%) | Â | Â | Â | <0.001 |
 White | 1095 (64.10) | 4636 (69.2) | 1833 (74.7) |  |
 Black | 203 (11.9) | 805 (12.0) | 208 (8.5) |  |
 Other | 410 (24.0) | 1256 (18.8) | 413 (16.8) |  |
SBP, mmHg | 120.6 (26.4) | 123.3 (26.3) | 121.9 (26.0) | <0.001 |
DBP, mmHg | 61.5 (18.6) | 62.2 (18.1) | 61.1 (17.3) | 0.021 |
Heart rate, beats/minute | 89.9 (20.9) | 88.6 (19.9) | 91.3 (20.0) | <0.001 |
Vasopressin use, n (%) | Â | Â | Â | <0.001 |
 Yes | 844 (49.4) | 2728 (40.7) | 1047 (42.7) |  |
 No | 864 (50.6) | 3969 (59.3) | 1407 (57.3) |  |
Ventilator use, n (%) | Â | Â | Â | <0.001 |
 Yes | 1063 (62.2) | 3528 (52.7) | 1316 (53.6) |  |
 No | 645 (37.8) | 3169 (47.3) | 1138 (6.4) |  |
Comorbidities | Â | Â | Â | Â |
 Cardiac arrhythmias, n (%) |  |  |  | <0.001 |
  Yes | 375 (22.0) | 1944 (29.0) | 696 (28.4) |  |
  No | 1333 (78.0) | 4753 (71.0) | 1758 (71.6) |  |
 Valvular disease, n (%) |  |  |  | 0.051 |
  Yes | 177 (15.7) | 740 (11.0) | 228 (9.3) |  |
  No | 1531 (89.6) | 5957 (89.0) | 2226 (90.7) |  |
 Pulmonary circulation, n (%) |  |  | 0.599 | |
  Yes | 97 (5.7) | 415 (6.2) | 158 (6.4) |  |
  No | 1611 (94.3) | 6282 (93.8) | 2296 (93.6) |  |
 Chronic pulmonary disease, n (%) |  |  |  | <0.001 |
  Yes | 255 (14.9) | 1343 (20.1) | 558 (22.7) |  |
  No | 1453 (85.1) | 5354 (79.9) | 1896 (77.3) |  |
 Liver disease, n (%) |  |  |  | <0.001 |
  Yes | 300 (17.6) | 492 (7.3) | 108 (4.4) |  |
  No | 1408 (82.4) | 6205 (92.7) | 2346 (95.6) |  |
 Lymphoma, n (%) |  |  |  | <0.001 |
  Yes | 59 (3.5) | 123 (1.8) | 49 (2.0) |  |
  No | 1649 (96.5) | 6574 (98.2) | 2405 (98.0) |  |
 Metastatic cancer, n (%) |  |  |  | <0.001 |
  Yes | 62 (3.6) | 280 (4.2) | 203 (8.3) |  |
  No | 1646 (96.4) | 6417 (95.8) | 2251 (91.7) |  |
 Solid tumor, n (%) |  |  |  | <0.001 |
  Yes | 93 (5.4) | 411 (6.1) | 248 (10.1) |  |
  No | 1615 (94.6) | 6286 (93.9) | 2206 (89.9) |  |
 Deficiency anemias, n (%) |  |  |  | 0.046 |
  Yes | 246 (14.4) | 1014 (15.1) | 416 (17.0) |  |
  No | 1462 (85.6) | 5683 (84.9) | 2038 (83.0) |  |
Laboratory parameters | Â | Â | Â | Â |
 PO2, mmHg | 118.0 (74.0–279.0) | 113.0 (75.0–237.0) | 107.0 (72.3–201.0) | <0.001 |
 PCO2, mmHg | 39.0 (34.0–46.0) | 40.0 (34.0–47.0) | 40.0 (34.0–47.0) | 0.036 |
 Serum potassium, mmol/L | 4.32 (0.89) | 4.39 (0.91) | 4.44 (0.95) | <0.001 |
 BUN, mg/dl | 30.0 (20.0–47.0) | 31.0 (21.0–49.0) | 33.0 (21.0–52.0) | <0.001 |
 Serum bicarbonate, mmol/L | 23.0 (19.0–26.0) | 24.0 (20.0–27.0) | 23.0 (20.0–27.0) | <0.001 |
 Serum pH | 7.31 (0.14) | 7.32 (0.12) | 7.32 (0.12) | <0.001 |
 White blood cell count, 109/L | 11.0 (7.4–16.5) | 10.6 (7.6–15.1) | 11.8 (8.1–16.5) | <0.001 |
 Neutrophil count, n (%) | 65.9 (18.2) | 77.6 (11.4) | 83.5 (12.9) | <0.001 |
 Lymphocyte count, n (%) | 19.0 (12.0–28.0) | 12.0 (8.0–17.7) | 5.9 (3.8– 8.8) | <0.001 |
 Platelet count, 109/L | 122.0 (67.0–182.) | 220.0 (164.0–287.0) | 285.0 (206.0–383.8) | <0.001 |
Scoring systems | Â | Â | Â | Â |
 GCS | 14.0 (6.0–15.0) | 15.0 (8.0–15.0) | 15.0(9.0–15.0) | <0.001 |
 SOFA | 7.0 (5.0–10.0) | 5.0 (3.0– 8.0) | 5.0 (3.0– 8.0) | <0.001 |
Renal function | Â | Â | Â | Â |
 Serum creatinine, mg/dl | 1.50 (1.10–2.40) | 1.60 (1.20–2.40) | 1.60 (1.20–2.50) | 0.340 |
 Urine output, ml/24 h | 1050 (372–2311) | 1050 (395–2325) | 900 (345–2095) | 0.046 |
 eGFR, ml/min/1.73 m2 | 0.88 (0.76–0.94) | 0.87 (0.77–0.95) | 0.84 (0.76–0.94) | <0.001 |
 eGFR change | 2.02 (1.17–4.27) | 1.15 (1.86–3.76) | 2.03 (1.25–4.16) | <0.001 |
 KDIGO stage, n (%) |  |  |  | 0.084 |
  Stage 1 | 1081 (63.4) | 4467(66.7) | 1589 (64.8) |  |
  Stage 2 | 407 (23.9) | 1456 (21.8) | 573 (23.3) |  |
  Stage 3 | 218 (12.8) | 776 (11.6) | 292 (11.9) |  |
 Renal replacement therapy |  |  |  | 0.008 |
  Yes | 71 (4.2) | 189 (2.8) | 66 (2.7) |  |
  No | 1635 (95.8) | 6510 (97.2) | 2388 (97.3) |  |